Format
Sort by
Items per page

Send to

Choose Destination

Best matches for O’Shaughnessy JA[au]:

Search results

Items: 1 to 50 of 105

1.

Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.

Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA.

Breast J. 2019 Sep;25(5):880-888. doi: 10.1111/tbj.13345. Epub 2019 Jul 9.

PMID:
31290203
2.

Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.

Jones VE, McIntyre KJ, Paul D, Wilks ST, Ondreyco SM, Sedlacek S, Melnyk A, Oommen SP, Wang Y, Peck SR, O'Shaughnessy JA.

Oncologist. 2019 Sep;24(9):1153-1158. doi: 10.1634/theoncologist.2018-0340. Epub 2019 Mar 4.

PMID:
30833486
3.

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.

Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A.

Mol Cancer Ther. 2019 Jan;18(1):204-212. doi: 10.1158/1535-7163.MCT-18-0243. Epub 2018 Oct 10.

4.

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.

Wilson TR, Udyavar AR, Chang CW, Spoerke JM, Aimi J, Savage HM, Daemen A, O'Shaughnessy JA, Bourgon R, Lackner MR.

Mol Cancer Res. 2019 Jan;17(1):97-108. doi: 10.1158/1541-7786.MCR-18-0619. Epub 2018 Aug 31.

PMID:
30171174
5.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.

6.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

7.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.

8.

The hedgehog pathway in triple-negative breast cancer.

Habib JG, O'Shaughnessy JA.

Cancer Med. 2016 Oct;5(10):2989-3006. doi: 10.1002/cam4.833. Epub 2016 Aug 18. Review.

9.

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.

Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF.

Cancer Med. 2016 Aug;5(8):1897-907. doi: 10.1002/cam4.761. Epub 2016 Jun 23. Review.

10.

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.

Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, Peacock NW, Bass JD, Burris HA 3rd, Hainsworth JD.

Breast Cancer Res Treat. 2015 Nov;154(1):89-97. doi: 10.1007/s10549-015-3599-5. Epub 2015 Oct 12.

PMID:
26456573
11.

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA.

Clin Breast Cancer. 2015 Dec;15(6):473-481.e3. doi: 10.1016/j.clbc.2015.04.008. Epub 2015 Apr 28.

12.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL.

Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7.

13.

Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS): commentary.

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2014 Mar;12 Suppl 7(3):17-22. No abstract available.

PMID:
25856456
14.

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.

Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA.

Breast Cancer Res. 2015 Dec 9;17(1):150. doi: 10.1186/s13058-015-0657-1.

15.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.

16.

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.

Robinson SD, O'Shaughnessy JA, Cowey CL, Konduri K.

Lung Cancer. 2014 Aug;85(2):326-30. doi: 10.1016/j.lungcan.2014.05.009. Epub 2014 May 21.

PMID:
24888229
17.

Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS).

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2014 Mar;12(3 Suppl 7):3-17. No abstract available.

PMID:
24870974
18.

Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer.

Christopher T, Gradishar WJ, O'Shaughnessy JA, Bramsen B, Lurie RH.

Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 4):1-14; quiz 15.

PMID:
24870601
19.

Effective management of quality of life in metastatic breast cancer.

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2014 Feb;12 Suppl 4(2):10-2. No abstract available.

PMID:
25856070
20.

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, Osborne CR, Anderson T, Krekow L, Blum JL, Pippen J, Florance A, Mahoney J, O'Shaughnessy JA.

BMC Res Notes. 2013 Dec 5;6:507. doi: 10.1186/1756-0500-6-507.

21.

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.

22.

Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.

Shen K, Qi Y, Song N, Tian C, Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy JA, Holmes FA, Asmar L, Pusztai L.

BMC Med Genomics. 2012 Nov 16;5:51. doi: 10.1186/1755-8794-5-51.

23.

Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.

O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, Harbeck N.

Oncologist. 2012;17(4):476-84. doi: 10.1634/theoncologist.2011-0281. Epub 2012 Mar 14. Review.

24.

Breast cancer in focus: treatment options for triple-negative metastatic breast cancer.

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2012 Jan;10(1):43-5. No abstract available.

PMID:
22398807
25.

Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?

Rugo HS, O'Shaughnessy JA, Perez EA.

Clin Adv Hematol Oncol. 2011 Nov;9(11):1-16.

PMID:
22355830
26.

Current treatment options for metastatic breast cancer: what now?

Rugo HS, O'Shaughnessy JA, Perez EA.

Clin Adv Hematol Oncol. 2011 Nov;9(11 Suppl 25):1-16.

PMID:
22362269
27.

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Robert NJ, Conkling PR, O'Rourke MA, Kuefler PR, McIntyre KJ, Zhan F, Asmar L, Wang Y, Shonukan OO, O'Shaughnessy JA.

Breast Cancer Res Treat. 2011 Feb;126(1):101-8. doi: 10.1007/s10549-010-1286-0. Epub 2010 Dec 25.

PMID:
21188632
28.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.

PMID:
21172893
29.

Lethal breast cancer.

O'Shaughnessy JA.

Clin Breast Cancer. 2010;10 Suppl 1:E6-7. doi: 10.3816/CBC.2010.s.001. No abstract available.

PMID:
20587408
30.

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.

Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Muscato J, O'Shaughnessy JA, Gralow J.

Clin Breast Cancer. 2010 Apr;10(2):148-53. doi: 10.3816/CBC.2010.n.020.

PMID:
20299319
31.

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.

Smith JW 2nd, McIntyre KJ, Acevedo PV, Encarnacion CA, Tedesco KL, Wang Y, Asmar L, O'Shaughnessy JA.

Breast Cancer Res Treat. 2009 Nov;118(2):361-7. doi: 10.1007/s10549-009-0410-5. Epub 2009 May 21.

PMID:
19459042
32.

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.

Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.

Breast Cancer Res Treat. 2009 Aug;116(3):521-7. doi: 10.1007/s10549-008-0284-y. Epub 2009 Jan 13.

PMID:
19139988
33.

RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.

O'Shaughnessy JA, Brufsky AM.

Clin Breast Cancer. 2008 Aug;8(4):370-3. doi: 10.3816/CBC.2008.n.045. No abstract available.

PMID:
18757267
34.

Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.

Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, Backner A, Bush JE, Gallion HH, Wells A, O'Shaughnessy JA.

Anticancer Res. 2008 May-Jun;28(3B):1733-40.

35.

Pegfilgrastim: recent advances in the prophylaxis of chemotherapy-induced neutropenia.

Reddy GK, O'Shaughnessy JA.

Support Cancer Ther. 2005 Apr 1;2(3):149-52. No abstract available.

PMID:
18628163
37.

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, Vukelja S, Orlando M, Vaughn LG, Zhan F, Boehm KA, O'Shaughnessy JA.

Clin Breast Cancer. 2008 Apr;8(2):178-86. doi: 10.3816/CBC.2008.n.019.

PMID:
18621615
38.

Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable.

Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D.

Clin Breast Cancer. 2008 Feb;8(1):33-7. doi: 10.3816/CBC.2008.n.046. Review.

PMID:
18501057
39.

Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.

O'Shaughnessy JA.

Clin Breast Cancer. 2007 Dec;8 Suppl 1:S11-21. Review.

PMID:
18282366
40.

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Dec;7(11):850-6. doi: 10.3816/CBC.2007.n.049.

PMID:
18269774
41.

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.

Ewer MS, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Jun;7(8):600-7. Review.

PMID:
17592672
42.

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.

Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Feb;7(6):465-70.

PMID:
17386123
43.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L.

J Clin Oncol. 2006 Dec 1;24(34):5381-7. Erratum in: J Clin Oncol. 2007 May 1;25(13):1819.

PMID:
17135639
44.

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.

Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA.

J Clin Oncol. 2006 Sep 20;24(27):4384-90. Epub 2006 Aug 22.

PMID:
16926223
45.

Molecular signatures predict outcomes of breast cancer.

O'Shaughnessy JA.

N Engl J Med. 2006 Aug 10;355(6):615-7. No abstract available.

PMID:
16899783
46.

Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.

O'Shaughnessy JA, Blum JL.

Clin Breast Cancer. 2006 Apr;7(1):42-50. Review.

PMID:
16764743
47.

Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.

O'Shaughnessy JA, Pluenneke R, Sternberg J, Khandelwal P, Ilegbodu D, Asmar L.

Clin Breast Cancer. 2006 Feb;6(6):505-10.

PMID:
16595033
48.

The global breast cancer burden: variations in epidemiology and survival.

Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS; ABREAST Investigators.

Clin Breast Cancer. 2005 Dec;6(5):391-401. Review.

PMID:
16381622
49.

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.

O'Shaughnessy JA, Clark RS, Blum JL, Mennel RG, Snyder D, Ye Z, Liepa AM, Melemed AS, Yardley DA.

Clin Breast Cancer. 2005 Jun;6(2):143-9.

PMID:
16001992
50.

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

O'Shaughnessy JA, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, George M, Von Hoff D.

Clin Breast Cancer. 2005 Feb;5(6):439-46.

PMID:
15748464

Supplemental Content

Loading ...
Support Center